| Literature DB >> 31118107 |
Nacim Louhichi1, Emna Bahloul2, Slaheddine Marrakchi2, Houda Ben Othman3, Chahnez Triki3, Kawthar Aloulou4, Lobna Trabelsi5, Nadia Mahfouth6, Zeineb Ayadi-Mnif7, Leila Keskes8, Faiza Fakhfakh9, Hamida Turki2.
Abstract
BACKGROUND: Chanarin-Dorfman syndrome (CDS) is a rare syndromic disease related to an accumulation of triacylglycerol in most organs. The aim of our study was to investigate various organs in a large series of CDS patients.Entities:
Keywords: ABHD5 gene; C.773(− 1)G > A mutation; CDS; Hypothyroidism; Splice site
Mesh:
Substances:
Year: 2019 PMID: 31118107 PMCID: PMC6529994 DOI: 10.1186/s13023-019-1095-4
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.123
Clinical features of the studied patients with Dorfman-Chanarin syndrome
| Patients | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| Family | 1 | 2 | 3 | 4 | 4 | 4 | 4 | 5 | 10 | 11 | 12 | 6 | 7 | 8 | 9 |
| Gender | F | F | M | M | M | M | M | M | M | M | F | F | F | M | F |
| Age (years) | 30 | 42 | 30 | 37 | 58 | 48 | 40 | 26 | 14 | 52 | 30 | 9 | 23 | 7 Mo | 7 Mo |
| Jordans’ anomaly |
| ND | ND |
| ND | ND | ND |
|
|
|
|
| ND |
| ND |
| TSH/ FT4 (0.25-5μUI/mL | (N/N)a | 9.42/10.06 | 0.9/14.72 | > 60/1.55 | 11.5/8.11 | 16.17/1084 | 11.87/8.79 | 2.25/17.32 | 3.02/18.21 | ND/ND | 4.5/11.5 | 2.82/18.65 | 3.30/18.53 | ND/ND | ND/ND |
| Thyroid antibodies | – |
| ND |
|
|
|
| ND | ND | ND | ND | ND | ND | ND | ND |
| AST/ALT | ▲/▲ | ▲/▲ | ▲/▲ | ▲/▲ | ▲/▲ | ▲/▲ | ▲/▲ | ▲/▲ | ▲/▲ | ▲/▲ | ▲/▲ | ▲/▲ | ▲/▲ | ND/ND | ND/ND |
| CPK | ND | ND | ND | ND | ND | ND | ND | ND | ▲ | ND | ▲ | ▲ | ▲ | ND | ND |
| Ocular findings | N | Nystagmus Hypermetropia | Cataract Amblyopia | ND | N | ND | ND | N | N | Cataract | Cataract | N | N | ND | ND |
| Hearing impairment/audiogram | N/SHI | N/SHI | N/SHI | N/ND | +/SHI | N/ND | N/ND | N/SHI | N/SHI | +/SHI | N/ND | N/SHI | N/ND | ND | ND |
| Cervical ultrasound | Hypo echogenic | Enlarged thyroid | Enlarged thyroid | ND | Hypo echogenic | Hypo echogenic | Hypo echogenic | Enlarged thyroid | Hyper echogenic | ND | Hyper echogenic | ND | ND | ND | ND |
| Abdominal ultrasound | HMG/ steatosis | HMG/ steatosis Poorly differenciated kidney | HMG/ steatosis Poorly differenciated kidney | ND | ND | ND | HMG/ steatosis Poorly differenciated kidney | HMG/ steatosis | HMG/ steatosis | HMG/ steatosis | HMG/ steatosis SMG enlarged kidney | HMG/ steatosis | ND | ND | ND |
F Female, M Male, Mo Months, N Normal, ND Not Done; ▲: increased; ▼: decreased; +: present; −: absent, TSH Thyroid Stimulating Hormone, FT4 Free Thyroxine, AST Aspartate Transaminase, ALT Alanine Transaminase, CPK Creatine Phosphokinase, SHI Sensorineural Hearing Impairment, SMG Splenomegaly, HMG Hepatomegaly
a: patient with hypothyroidism under L-thyroxine substitution therapy
Fig. 1Distribution of clinical, radiological data of patients for each analysis. Abdominal ultrasonography liver (Abd us liver), Abdominal ultrasonography kidney (Abd us kidney), Thyroid Stimulating Hormone (TSH), Free Thyroxine (FT4), Aspartate Transaminase (ASAT), Alanine Transaminase (ALAT), Creatine Phosphokinase (CPK), Magnetic Resonance Imaging (MRI)
Fig. 2Cervical MRI for patient 1 with In-Phase sequence (IP) (a) and Out-Of-Phase sequence (OOP) (b) showing drop of signal intensities. Cervical MRI for patient 1 shows lipid-rich thyroid gland. In-Phase sequence (IP) (a) demonstrates an intermediate signal (arrow). Out-of-phase sequence (b), thyroid gland shows a reduction of signal intensity (arrow), indicating that the gland is most likely infiltrated by lipids. This signal intensity difference is related to difference between water and fat protons resonance frequencies
FT4 and TSH values in healthy relatives of family 1, 2 and 4
| Families | Age | FT4 (9–20 pmol/L) | TSH (0.25–5 μIU/mL) |
|---|---|---|---|
| Family 1 | |||
| II.3 | 62 | 12.69 | 1.63 |
| II.4 | 56 | 12.76 | 2.11 |
| III.2a | 29 | N | N |
| Family 2 | |||
| II.3 | 79 | 14.30 | 1.69 |
| II.4 | 69 | 17.36 | 2.03 |
| III.3 | 39 | 16.60 | 1.75 |
| III.4 | 34 | 17.45 | 3.70 |
| Family 4 | |||
| III.2 | 75 | 11.16 | 3.25 |
| IV.6 | 45 | 10.42 | 4.79 |
| IV.7 | 51 | 12.00 | 3.00 |
| IV.8 | 55 | 11.75 | 3.81 |
a Known hypothyroidism under L-thyroxine substitution therapy